曲美他嗪对慢性心力衰竭患者再住院率的影响

摘要

目的：观察曲美他嗪对慢性心力衰竭患者再住院率及病死率的影响。方法选择2009年6月至2011年2月在东光县医院住院的19O例慢性心力衰竭患者,经随机抽样法分为曲美他嗪组100和常规组90例。常规组给予地高辛、β受体阻滞剂、利尿剂、血管紧张素转换酶抑制剂、醛固酮拮抗剂等常规治疗,曲美他嗪组在常规组治疗基础上口服曲美他嗪20 mg,每日3次。观察患者6个月、1年和2年再住院率及病死率。结果两组患者6个月、1年和2年再住院率比较,差异均有统计学意义(P<0.05)；病死率比较,差异无统计学意义。结论曲美他嗪治疗慢性心力衰竭安全有效；能降低患者再住院率,但对病死率无影响。%Objective To observe the effect of Trimetazidine in treatment of Chronic heart failure. Methods 190 cases of Chronic heart failure,Who were in Dongguang County Hospital during June 2009 to February 2011,were simple random sampling divided into control group(100 cases) and observation group (90 cases). The conventional group received conventional treatment of Digoxin,β-receptor blocking,Diuret-ics,Angiotensin converting enzyme inhibitor,and Aldosterone antagonists. While the trimetazidine group was given an extra Oral 20mg trimetazidine three times a day on the base of conventional treatment. Then the re-hospitalization rate and hospital mortality rate of both groups were observed at 6 months, 1 and 2 years sepeartely. Results Comparing with the rehospitalization rate and the mortality rate of both groups at 6 months,1 and 2 years sepeartely,the rehospitalization rate has statistically significant(P <0. 05)and the mortality rate has no obvious difference. Conclusion Trimetazidine in treatment of Chronic heart failure is safe and efective. And it can reduce rehospitalization rate and has no influence on mortality rate.